INVESTORS

Carticept is a privately held company funded by two of the nation’s leaders in medical device venture investing, Domain Associates
and New Enterprise Associates, and by corporate partner SonoSite, Inc.

Domain Associates

Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on life sciences. With $2.5 billion of capital
under management, Domain's three major investment segments are pharmaceuticals, specialty pharmaceuticals and medical devices, while
additional areas of interest include biomaterials, bioinstrumentation and diagnostics. The Partners of Domain have a total of close to 200
person-years of experience among them in the healthcare/venture capital industries and have been involved in the formation and growth of
more than 200 life-sciences companies. The highly focused network, experience, and reputation of this team have made it one of the top
private-equity groups participating in the healthcare field.

http://www.domainvc.com/

New Enterprise Associates

New Enterprise Associates, Inc. (NEA) is a leading venture capital firm focused on helping entrepreneurs create and build major new
enterprises that use technology to improve the way we live, work and play. Since its founding in 1978, the firm has followed the same
core principles: supporting its entrepreneurs, providing an excellent return to its limited partners and practicing its profession with
the highest standards and respect. Through its affiliated funds, NEA focuses on investments at all stages of a company’s development,
from seed stage through IPO. With approximately $11 billion in committed capital, NEA’s experienced management team has invested in
over 650 companies, of which more than 160 have gone public and more than 245 have been acquired.

www.nea.com

SonoSite, Inc.

Sonosite, Inc. is the innovator and world leader in bedside and point-of-care ultrasound and an industry leader in ultra high-frequency micro-ultrasound technology and impedance cardiography equipment.  Headquartered near Seattle, the company is represented by fourteen subsidiaries and a global distribution network in over 100 countries.  SonoSite's small, lightweight systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high-performance ultrasound to the point of patient care.

www.sonosite.com